Bioray Biotech Co

Bioray Biotech Co AAQS

The The AAQS of Bioray Biotech Co (7561.TWO) as of Oct 20, 2026 is 2. In the previous year, The AAQS was 2.00 — a change of 0.00% (lower).

AAQS

2

YoY

0.00%

Last updated:

Bioray Biotech Co has a current AAQS of 2.

A high AAQS can be seen as a positive indicator that the company is developing successfully.

Investors can assume that the company is on a good path to generate profits.

On the other hand, it is important to consider the AAQS of the stock Bioray Biotech Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.

In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.

The Bioray Biotech Co AAQS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

AAQS
Date
AAQS
Jan 1, 2018
2.00 TWD
Jan 1, 2019
2.00 TWD
Jan 1, 2020
2.00 TWD
Jan 1, 2021
2.00 TWD
Jan 1, 2022
2.00 TWD
Jan 1, 2023
2.00 TWD
Jan 1, 2024
2.00 TWD
Jan 1, 2025
2.00 TWD
The Bioray Biotech Co AAQS history
YEARAAQSYoY
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
20.00%
2—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioray Biotech Co Stock analysis

What does Bioray Biotech Co do? BioRay Biotech Co., Ltd. generates revenue through its biological health products, functional medical testing services, and cell storage and preparation offerings. The company sells personalized probiotics, anti-allergic and intestinal probiotics, diabetes probiotics, female urinary tract products, and anti-arthritis probiotics. Functional medical testing includes personalized bacteria, personalized fungi, intestinal normal bacteria, quantitative magnesium detection in red blood cells, metabolic gene polymorphism analysis, and lymphocyte grouping. Cell storage services feature stem cell storage, immune cell storage, and cytokine induced killer (CIK) immune cell preparations. The primary customers for these products and services are individuals seeking personalized health solutions, including those managing chronic conditions like diabetes or arthritis. The company targets health-conscious consumers and medical professionals requiring specialized testing and cell-based therapies. BioRay Biotech focuses on delivering tailored health and medical services through its integrated product and service portfolio. Revenue streams are derived from direct sales of health products, testing service fees, and cell storage contracts. The business model emphasizes customization, with each product and service segment catering to specific health needs. The company’s offerings are structured to address individual health challenges through scientific and personalized approaches. Bioray Biotech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioray Biotech Co stock

The AAQS of Bioray Biotech Co is 2 in 2025.

On Eulerpool you can find the complete historical development of The AAQS Bioray Biotech Co since 2006 – with annual values, charts, and detailed analysis.

The AAQS is a key figure developed by AlleAktien.

The AAQS is a key figure developed by AlleAktien.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Bioray Biotech Co

All Key Metrics — Bioray Biotech Co